The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Year-end report January – December 2024
The Group in summary 01/10/24 01/10/23 Full year Full year -31/12/24 -31/12/23 2024 2023 Net sales 4 127 1 626 11 787 8 015 Operating loss -18 505 -20 823 ...Intervacc AB (publ) publishes prospectus regarding the rights issue
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER...Report from Extraordinary General Meeting in Intervacc
Intervacc AB (publ) held an Extraordinary General Meeting (”EGM”) on Friday 31 January 2025, whereby it was resolved to approve the Board of Directors’ proposal to amend the Articles of Association and to approve the Board of Directors’ resolution on a rights issue....Intervacc has received orders from Dechra Pharmaceuticals with an order value equivalent to approximately SEK 5.8 million
Stockholm, January 16, 2025 – Intervacc AB (publ) has received orders from Dechra Pharmaceuticals with a total order value equivalent to approximately SEK 5.8 million. Orders received relate to Strangvac®, a vaccine against the highly contagious and serious...Nyhetstjänster
